Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-07-27 00:00:00 ET · period of report 2023-06-29 · accession 0001209191-23-043579 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-27 | 2023-06-29 | RXRX | Borgeson Blake | Dir | G - Gift | $0.00 | -14.0K | 7.51M | -0.2% | $0 | |
| 2023-07-27 | 2023-07-25 | RXRX | Borgeson Blake | Dir | S - Sale | $14.61 | -18.7K | 7.49M | -0.2% | -$273.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-06-29 | G | D | 14,000 | $0.00 | 7,506,104 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-07-25 | S | D | 18,719 | $14.61 | 7,487,385 | D | — | — | (F2) The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14.16 to $15.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. |